Login / Signup

AAV-ie enables safe and efficient gene transfer to inner ear cells.

Fangzhi TanCenfeng ChuJieyu QiWenyan LiDan YouKe LiXin ChenWeidong ZhaoCheng ChengXiaoyi LiuYunbo QiaoBing SuShuijin HeChao ZhongHuawei LiRenjie ChaiGuisheng Zhong
Published in: Nature communications (2019)
Hearing loss is the most common sensory disorder. While gene therapy has emerged as a promising treatment of inherited diseases like hearing loss, it is dependent on the identification of gene delivery vectors. Adeno-associated virus (AAV) vector-mediated gene therapy has been approved in the US for treating a rare inherited eye disease but no safe and efficient vectors have been identified that can target the diverse types of inner ear cells. Here, we identify an AAV variant, AAV-inner ear (AAV-ie), for gene delivery in mouse inner ear. Our results show that AAV-ie transduces the cochlear supporting cells (SCs) with high efficiency, representing a vast improvement over conventional AAV serotypes. Furthermore, after AAV-ie-mediated transfer of the Atoh1 gene, we find that many SCs trans-differentiated into new HCs. Our results suggest that AAV-ie is a useful tool for the cochlear gene therapy and for investigating the mechanism of HC regeneration.
Keyphrases
  • gene therapy
  • hearing loss
  • induced apoptosis
  • cell cycle arrest
  • high efficiency
  • stem cells
  • oxidative stress
  • endoplasmic reticulum stress
  • copy number
  • genome wide
  • cell death
  • transcription factor
  • drug administration